Phio Pharmaceuticals (PHIO)
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It deve...
- Open
- 1.060
- High
- 1.060
- Low
- 1.030
- Prev. Close
- 1.060
- Volume
- 81.90K
- Turnover
- 85.74K
- Avg Price
- 1.047
- Bid/Ask Ratio
- --
- Amplitude
- 2.83%
- 52wk High
- 4.190
- Volume Ratio
- 0.34
- Turnover Ratio
- 0.71%
Phio Pharmaceuticals Analyst Rating
View moreForecast & Rating
Aug 7, 2026Price forecast
$14.001233.33%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 14 at 03:08 PM
Phio Pharmaceuticals announces annual shareholder meeting
- PUBT · Aug 11 at 06:04 AM
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894
- Earnings Watch · Aug 6 at 04:11 PM
Phio Pharmaceuticals | 8-K: FY2026 Q2 Revenue: USD 0
- PUBT · Aug 6 at 03:37 PM
Phio net loss widens to $4.14 million in Q2 FY26
- PUBT · Jul 30 at 03:02 PM
Phio Pharmaceuticals director Ronald Todd Plott files initial beneficial ownership statement
- PUBT · Jul 22 at 11:31 AM
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation
